Vera pulls forward ORIGIN 3 kidney-function readout for atacicept to Q3 2026
The FDA-aligned eGFR analysis will test whether atacicept's proteinuria benefit in IgA nephropathy extends to slowing kidney function decline, the data full approval will rest on.
Executive Summary
- Vera Therapeutics and the FDA agreed to move up the kidney-function analysis in atacicept's pivotal IgA nephropathy trial, compressing a data timeline that previously ran into 2027.
- The trial's earlier interim analysis showed atacicept beat placebo on proteinuria reduction, the finding that supported both an accelerated-approval filing and the FDA's willingness to pull the kidney-function analysis forward.
- Kidney function, not proteinuria, is the harder confirmatory bar regulators want before granting full approval, and the field's history in this target class has not been kind to that transition.
- Atacicept sits among several BAFF- and APRIL-targeted programs in IgA nephropathy, an approach that has already failed for multiple sponsors, sharpening what a positive kidney-function signal here would mean for the class.
The timing change
Vera Therapeutics said on June 2, 2026 that it aligned with the FDA on a revised eGFR analysis plan for ORIGIN 3, the Phase 3 trial of atacicept in IgA nephropathy (NCT04716231). The eGFR results, which measure change in kidney filtration function, are now expected in the third quarter of 2026, pulled forward from a prior 2027 plan. Pending a positive result, Vera plans to submit a supplemental Biologics License Application for full approval in the fourth quarter of 2026. VeraVera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to ...Jun 2, 2026
What already read out
The move follows a positive signal on a different endpoint: the trial's prespecified week-36 interim analysis showed atacicept reduced urine protein-to-creatinine ratio (UPCR), a marker of protein leakage into urine, by 46% from baseline and by 42% versus placebo, with a p-value below 0.0001. That proteinuria result, along with eGFR data from the earlier ORIGIN Phase 2b trial, is what Vera and the FDA cited in support of moving the kidney-function analysis earlier. NCT04716231+1Atacicept in Subjects With IgA NephropathyNCT04716231Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to ...Jun 2, 2026
The regulatory context
Atacicept already holds FDA Breakthrough Therapy Designation for IgA nephropathy, granted based on the Phase 2b data, and Vera has stated it is pursuing accelerated approval on the proteinuria endpoint with a pending BLA. The eGFR analysis is the confirmatory kidney-function evidence the FDA has indicated it wants to see before converting that into full approval. Marshall Fordyce, M.D., founder and CEO of Vera Therapeutics, said the company is "excited for the potential to deliver the first approved therapy targeting both BAFF and APRIL in adults with IgAN". VeraVera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to ...Jun 2, 2026
The trial's operational path
ORIGIN 3 enrolled 376 patients against an original enrollment plan that was revised several times, including an increase to 492 patients in May 2023 before settling at 376 weeks later. The trial's primary completion date moved from December 2022 to May 2025 across four amendments, and the study has remained in Active, not recruiting status since April 2025. Those changes reflect protocol churn typical of a multi-year registrational trial rather than a signal about the eGFR result itself. Vera+1Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to ...Jun 2, 2026Atacicept in Subjects With IgA NephropathyNCT04716231
The competitive field
Atacicept, a fusion protein that blocks both BAFF and APRIL, competes in an IgA nephropathy field with sibeprenlimab and zigakibart, both of which target APRIL alone through monoclonal antibodies, and with other BAFF-directed programs including telitacicept and povetacicept in related autoimmune indications. Among resolved trials in the BAFF-and-IgA-nephropathy pairing, one completed and three terminated, a 75% termination rate across three distinct sponsors. Atacicept's own earlier Phase 2 trial in IgA nephropathy, run by EMD Serono, was also terminated. Against that backdrop, a kidney-function result that holds up on longer follow-up would be the evidence that distinguishes atacicept's mechanism from the class's prior attempts in this indication.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.